Summary
Quest Diagnostics Incorporated (DGX) announced on May 19, 2016, that it has entered into an Accelerated Share Repurchase (ASR) agreement with Morgan Stanley & Co. LLC to buy back approximately $250 million of its common stock. This ASR is part of the company's ongoing common stock repurchase program, indicating a strategic move to return capital to shareholders and potentially boost earnings per share. The company made an initial payment of $250 million on May 20, 2016, and received approximately 2.79 million shares immediately. The final number of shares repurchased will be determined by the volume-weighted average price during a specified period, adjusted for a discount and other terms. This transaction is expected to conclude by the third quarter of 2016, signaling a significant capital allocation decision by Quest Diagnostics.
Key Highlights
- 1Quest Diagnostics entered into an Accelerated Share Repurchase (ASR) agreement valued at $250 million.
- 2The ASR is part of the company's existing common stock repurchase program.
- 3An initial payment of $250 million was made on May 20, 2016.
- 4The company received an initial 2,790,179 shares of common stock on May 20, 2016.
- 5The final number of shares repurchased will be based on the volume-weighted average price during a repurchase period, with a discount.
- 6The transaction is anticipated to be completed in the third quarter of 2016.